High efficacy, selectivity and cellular targeting of therapeutic agents has been an active area
of investigation for decades. Currently, most clinically approved therapeutics are small …

The delivery of therapeutic agents faces significant hurdles posed by the endo-lysosomal
pathway, a bottleneck that hampers clinical effectiveness. This comprehensive review …

Regulating cell function and tissue formation by combining gene delivery with functional
scaffolds to create gene-activated matrices (GAMs) is a promising strategy for tissue …

The blood-brain barrier (BBB) is a highly selective biological barrier that represents a major
bottleneck in the treatment of all types of central nervous system (CNS) disorders. Small …

Nanogels (NG) are among the most ideal cytoplasmic protein delivery vehicles; however,
their performance is suboptimal, partly owing to relatively big size, poor cell uptake, and …

Numerous endosomolytic agents have been developed to facilitate nanoparticle escape
from the endosome and prevent destruction in the lysosome. Many endosomolytic agents …

The development of carriers for the delivery of oligonucleotide therapeutics is essential for
the successful translation of gene therapies to the clinic. In the present study, a delivery …

Glioblastoma multiforme is a devastating disease that has attracted enormous attention due
to poor prognosis and high recurrence. Small interfering RNA (siRNA) in principle offers a …

Gene therapy is the most effective treatment option for diseases, but its effectiveness is
affected by the choice and design of gene carriers. The genes themselves have to pass …

Small interfering RNAs (siRNA) provide a novel and highly specific therapy due to their
ability to effectively silence target genes, to date six siRNA therapeutics are approved for …